Turning to a clinical trial setting, the peptide– Fc fusion protein (AMG386/trebaninib) which blocks the binding of both Ang1 and Ang2 to Tie2, has struggled in three Phase III advanced ovarian cancer trials. Here, ANGPT1 is linked to ovarian cancer.